Genérico Ropinirole - Requip
|
Farmacia Online de máxima seriedad, confianza y seguridad
Envíos discretos hasta su casa u oficina
|
|
|
Lista de categorías
AnalgésicosAntibióticosAntidepresivosAntiinflamatoriosDisfunción EréctilPérdida De PesoSalud Masculina
Debo excusarme - pensaba que ustedes querian engañarme. Pero la demora era causada por un error. Recibí el encargo el jueves 8 de junio, y el otro el sábado 10 de junio. ¡ Tardo casi un mes pero fue a causa de un error en los datos de envio! Muchas gracias. - Curt
Nuestra página de facturación está certificada por:
- Actavis wins FDA approval for Ropinirole extended-release tablets - Pharmaceutical Business Review
Actavis wins FDA approval for Ropinirole extended-release tabletsPharmaceutical Business ReviewActavis Group, a generic pharmaceuticals company, has gained FDA approval for Ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg.
- Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended ... - MarketWatch (press release)
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended .
- Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip - The Pharma Letter
Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic RequipThe Pharma LetterSeparately, Switzerland headquartered Actavis Group, which is currently the subject of a 4.
- NuPathe Announces First Quarter 2012 Financial Results and Operational Highlights - MarketWatch (press release)
NuPathe Announces First Quarter 2012 Financial Results and Operational HighlightsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery.
- Safeguard Scientifics Announces First Quarter 2012 Financial Results - MarketWatch (press release)
Safeguard Scientifics Announces First Quarter 2012 Financial ResultsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery.
 |
Agregar a favoritos |
|---|
 |
Apuntarse a lista de correo |
|---|
Copyright © www.eurpharmacy.com. Todos los derechos reservados.